Industry News (Therapy)

Neupogen Approved for Use in U.K. for Advanced HIV

Published in AIDS Weekly, March 18th, 1996

Amgen, Thousand Oaks, California, announced that its recombinant granulocyte colony-stimulating factor (rHuG-CSF) Neupogen (Filgrastim) has been approved for use in the United Kingdom (U.K.) as a supportive therapy to treat neutropenia in people with advanced HIV infection, enabling them to receive myelosuppressive therapies.

Neutropenia is a condition caused by too few neutrophils, a type of white blood cell that is the body's first defense against infection. Neupogen is the first rHuG-CSF to be licensed for this use. The approved use for people with advanced HIV infection and neutropenia (Absolute Neutrophil Counts, or ANC, below 1,000) enables patients to receive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-03-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry